GenScript’s comprehensive solutions support your antibody drug discovery and development from target identification to lead generation and optimization to preclinical and clinical stages. We aim to simplify your work while providing a specialized process with our integrated series of precise and consistent scalable solutions to facilitate each principal milestone in antibody drug discovery. We combine speed and quality to get you through IND and onto clinical trials.

Antibody Drug Discovery

Antibody Drug Discovery Workflow

Lead Generation & Optimization 2

Target Identification

Understanding Disease Mechanism: Antibody therapeutics are used to combat different diseases such as cancers, autoimmune disease, infectious disease and more. Many technologies are available to identify a target and are often used in combination, these include but are not limited to: biochemical methods, genetic interactions, and computational inference.

Target Gene Validation: To validate targets, scientists use techniques such as cell-based models, phenotypic models, IHC, FACS, WB, for target engagement to demonstrate that the target is involved in the progression of a given disease.

Lead Identification & Optimization

Innovative techniques, such as phage display, advanced hybridoma technology, and single-cell sequencing, are utilized to generate diverse libraries of antibodies, allowing the identification of highly specific and potent leads. These methodologies enable rapid screening and selection of antibody candidates based on their functionality, affinity, and stability, thereby streamlining the lead identification process.

Following the identification and optimization of antibody leads, advanced technologies like antibody sequencing and humanization, ensure that the selected candidates are thoroughly characterized and prepared for the subsequent stages of the drug development process, setting the stage for the successful translation of research into potential therapeutic interventions.

Preclinical Studies

Once a lead is confirmed, the preclinical phase of drug development begins with in vivo research on non-human subjects for efficacy, toxicity, and pharmacokinetic (PK) data collection. After completion, scientists review and determine whether the drug can be moved to clinical trials in people.

The IND application identifies the intended use of the treatment for a condition and will outline manufacturing information and clinical protocols. The data collected during the preclinical stage will support movement to clinical trials by demonstrating preliminary safety and efficacy.

Clinical Studies

The clinical trial assesses drug safety and efficacy in healthy volunteers and patients. The data collected will help establish pharmacokinetics (ADME: absorption, distribution, metabolism, and elimination) within the body, as well as any side effects for safe dosage ranges. The clinical trial design is complex and its high cost and implementation issues can affect each stage carried out through its duration.


Learn more about our technologies to support antibody drug discovery. Find the information you need in our educational materials database.

img bg

Reproducible and reliable research starts with high quality materials. Interested in accelerating your research with us?

Speak To A Specialist

Do you like the current new website?